Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20553331 | 1.00 | MEN1 (0.67) | MEN1OPRM1OPRD1KMT2ALMNA | |
| SCHEMBL21775559 | 1.00 | MEN1 (0.67) | MEN1OPRM1OPRD1KMT2ALMNA | |
| SCHEMBL7367871 | 0.94 | MEN1 (0.63) | MEN1OPRM1OPRD1KMT2ALMNA | |
| SCHEMBL8825150 | 0.90 | MEN1 (0.70) | MEN1OPRM1OPRD1KMT2ALMNA | |
| SCHEMBL11449949 | 0.89 | MEN1 (0.68) | MEN1OPRM1OPRD1KMT2ALMNA | |
| SCHEMBL6690111 | 0.86 | MEN1 (0.65) | MEN1OPRM1OPRD1KMT2ALMNA | |
| SCHEMBL7327969 | 0.86 | MEN1 (0.68) | MEN1OPRM1OPRD1KMT2ALMNA | |
| SCHEMBL7367855 | 0.85 | MEN1 (0.63) | MEN1OPRM1OPRD1KMT2ALMNA | |
| SCHEMBL11606524 | 0.85 | MEN1 (0.71) | MEN1OPRM1OPRD1KMT2ALMNA | |
| SCHEMBL9363727 | 0.84 | ADRB1 (0.79) | MEN1OPRM1OPRD1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | MEN1 3248/4885OPRM1 81/4885OPRD1 157/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | MEN1 3011/4885OPRM1 40/4885OPRD1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.